on 03 May 2022
Last Applicant/ Owned by
Hyangnam-eup, Hwaseong-si
Gyeonggi-do
KR
18623
Serial Number
90696094 filed on 07th May 2021
Registration Number
6717900 registered on 03rd May 2022
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction and pelvic pain; Pharmaceutical p Read More
Botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction and pelvic pain; Pharmaceutical preparations, namely, acne medications, acne treatment preparations, adrenal hormone preparations, alcohol for topical use, allergy and allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretics, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, chemical compounds for drug delivery, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, vaccine adjuvants, vaccine stabilizers, diuretics, amino acids for medical purposes; Medicines for the treatment of gastrointestinal diseases; chemical preparations for pharmaceutical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; chemico-pharmaceutical preparations for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; drugs for medical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; Medicines for human purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; pharmaceutical preparations for activating cellular function; Adjuvants for medical purposes; pharmaceutical preparations for central nerve treatment, namely, for the treatment of sequelae caused by damage to the central nerve in the brain; dermatological pharmaceutical products, namely, injectable botulinum toxin for refining wrinkles; pharmaceutical preparations for treating skin disorders; antibiotic preparations; pharmaceutical preparations for chemical disorder treatment, namely, for treatment of chemical imbalance in the brain
No 90696094
No Service/Collective Mark
No
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
03rd May 2022 | REGISTERED-PRINCIPAL REGISTER |
15th Feb 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
15th Feb 2022 | PUBLISHED FOR OPPOSITION |
26th Jan 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
12th Jan 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
12th Jan 2022 | ASSIGNED TO EXAMINER |
09th Aug 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
11th May 2021 | NEW APPLICATION ENTERED IN TRAM |